Stockscreener 앱 받기
3.77
4.31%
-0.17
시간 외 거래:
3.80
0.03
+0.80%
전일 마감가:
$3.94
열려 있는:
$3.92
하루 거래량:
70,472
Relative Volume:
0.09
시가총액:
$76.01M
수익:
$264.74M
순이익/손실:
$-49.71M
주가수익비율:
-0.9204
EPS:
-4.0959
순현금흐름:
$-43.55M
1주 성능:
-3.58%
1개월 성능:
+24.42%
6개월 성능:
+93.33%
1년 성능:
-54.14%
1일 변동 폭
$3.62
$4.1399
1주일 범위
$3.51
$4.24
52주 변동 폭
$1.305
$12.26
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
명칭
Camp 4 Therapeutics Corp
전화
617-651-8867
주소
ONE KENDALL SQUARE, CAMBRIDGE, CA
CAMP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
3.77 | 79.43M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-16 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-05-27 | 개시 | Wedbush | Outperform |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | William Blair | Outperform |
| 2022-08-16 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2021-12-22 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2021-09-24 | 재확인 | Craig Hallum | Buy |
| 2021-06-25 | 재확인 | Craig Hallum | Buy |
| 2020-12-18 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2020-04-17 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-03-05 | 재확인 | Craig Hallum | Buy |
| 2019-12-20 | 재확인 | Craig Hallum | Buy |
| 2019-12-20 | 다운그레이드 | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-05-01 | 재확인 | Craig Hallum | Buy |
| 2019-03-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-01-25 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-12-21 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2018-12-14 | 재확인 | B. Riley FBR | Buy |
| 2018-12-11 | 다운그레이드 | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | 개시 | Goldman | Neutral |
| 2018-10-15 | 개시 | Jefferies | Hold |
| 2018-09-28 | 재확인 | Craig Hallum | Hold |
| 2018-04-27 | 재확인 | Craig Hallum | Hold |
| 2018-03-08 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-02-16 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
모두보기
Camp 4 Therapeutics Corp 주식(CAMP)의 최신 뉴스
Chart based exit strategy for Camp4 Therapeutics Corporation2025 Price Momentum & Consistent Income Trade Ideas - newser.com
Does Camp4 Therapeutics Corporation qualify in momentum factor screeningQuarterly Profit Review & Long Hold Capital Preservation Plans - newser.com
How Camp4 Therapeutics Corporation stock trades before earningsMarket Movement Recap & Long-Term Investment Growth Plans - newser.com
Risk adjusted return profile for Camp4 Therapeutics Corporation analyzedJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Can Camp4 Therapeutics Corporation stock sustain revenue growth2025 Earnings Surprises & Real-Time Volume Trigger Notifications - newser.com
How Camp4 Therapeutics Corporation stock reacts to global recession fearsLayoff News & Smart Swing Trading Techniques - newser.com
Real time breakdown of Camp4 Therapeutics Corporation stock performanceJuly 2025 Technicals & Verified Momentum Stock Alerts - newser.com
Can Camp4 Therapeutics Corporation stock weather global recessionGap Up & Safe Swing Trade Setups - newser.com
How moving averages guide Camp4 Therapeutics Corporation trading2025 Trading Volume Trends & Fast Moving Market Watchlists - newser.com
Can Camp4 Therapeutics Corporation stock reach $100 price targetCEO Change & Low Risk High Win Rate Picks - newser.com
What to do if you’re stuck in Camp4 Therapeutics CorporationWeekly Gains Summary & Smart Money Movement Alerts - newser.com
How to interpret RSI for Camp4 Therapeutics Corporation stockJuly 2025 Rallies & High Yield Stock Recommendations - newser.com
Volume spikes in Camp4 Therapeutics Corporation stock – what they meanStop Loss & High Accuracy Swing Entry Alerts - newser.com
Published on: 2025-10-19 02:06:54 - nchmf.gov.vn
Is Camp4 Therapeutics Corporation stock a safe buy before earningsJuly 2025 Recap & Weekly Momentum Picks - Trung tâm Dự báo KTTV quốc gia
Can Camp4 Therapeutics Corporation stock sustain market leadershipInflation Watch & Stock Portfolio Risk Control - nchmf.gov.vn
Combining price and volume data for Camp4 Therapeutics CorporationJuly 2025 Update & Real-Time Chart Pattern Alerts - newser.com
CAMP4 Therapeutics CorporationCommon Stock (NQ: - FinancialContent
3 Healthcare Companies Insiders Are Buying - The Globe and Mail
Is Camp4 Therapeutics Corporation a good long term investmentCup and Handle Formations & Low Entry Investment Portfolio - earlytimes.in
CAMP Form 3: Dr. Tardiff Discloses 74,578 Stock Options - Stock Titan
Will Camp4 Therapeutics Corporation continue its uptrendPortfolio Return Report & AI Powered Market Entry Ideas - newser.com
CAMP4 Therapeutics stock soars after $100 million private placement By Investing.com - Investing.com Nigeria
[SCHEDULE 13G] Camp4 Therapeutics Corp SEC Filing - Stock Titan
CAMP4 Aims For The Summit: Unlocking The Therapeutic Power Of RegRNA, Once Deemed Undruggable - RTTNews
Camp4 Therapeutics Corporation Stock Analysis and ForecastSector Performance Review & Unlock Long-Term Capital Growth Ideas - earlytimes.in
Cantor Fitzgerald initiates CAMP4 Therapeutics stock with Overweight rating - Investing.com
CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy By Investing.com - Investing.com Nigeria
Camp4 Therapeutics initiates GLP toxicology studies for CMP-SYNGAP-01 - MarketScreener
CAMP4 Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - TipRanks
CAMP4 Therapeutics begins toxicology studies for SYNGAP1 therapy - Investing.com India
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 - GlobeNewswire
Potential Breakthrough for Rare Brain Disorder: CAMP4's SYNGAP1 Drug Enters Final Pre-Clinical Stage - Stock Titan
What analysts say about Camp4 Therapeutics Corporation stockReal Estate Investment Trusts & These 3 Stocks Could Change Your Portfolio - Early Times
Camp 4 Therapeutics Corp (CAMP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Camp 4 Therapeutics Corp 주식 (CAMP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
1.45%
0.86%
자본화:
|
볼륨(24시간):